Search

everythinglearnresearchcommunity

for

Search:↓

A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.

The issue covers reproductive health topics like cancer markers, incontinence treatments, and the impact of pre-term birth.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

Balding and low testosterone increase risk of urinary stones.

Germacrene analogs, especially 8-Hydroxy germacrene B, are more effective than germacrone at blocking a hormone-related enzyme and could help treat hair loss.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

5α-reductase inhibitors like finasteride and dutasteride can help treat skin disorders stimulated by androgens, such as hair loss and acne.

High androgen levels can cause excessive hair growth and may indicate serious health issues, including heart disease and fertility problems.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Certain interactions help prepare the androgen receptor for pairing and activation, which is important for its role in development and disease.

Spironolactone does not increase the risk of breast cancer recurrence.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Mutations in the androgen receptor gene cause androgen insensitivity, leading to female traits in genetically male individuals.

Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.

ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.